-
Web-based treatment for substance use disorders: Differential effects by primary substance.
Cochran G, Stitzer ML, Campbell ANC, Hu M, Vandrey R, Nunes EV. Web-based treatment for substance use disorders: Differential effects by primary substance. Addictive Behaviors 2015;45:191-194.
-
The use of technology in participant tracking and study retention: Lessons learned from a Clinical Trials Network study.
Mitchell SG, Schwartz RP, Alvanzo AAH, Weisman MS, Kyle TL, Turrigiano EV, Gibson ML, Perez L, McClure EA, Clingerman S, Froias A, Shandera DR, Walker NR, Babcock DL, Bailey GL, Miele GM, Kunkel LE, Norton M, Stitzer ML. The Use of Technology in Participant Tracking and Study Retention: Lessons Learned from a Clinical Trials Network Study. Substance Abuse 2015;36(4):420-426.
-
Comorbidities and race/ethnicity among adults with stimulant use disorders in residential treatment.
Sanchez K, Chartier KG, Greer TL, Walker NR, Carmody T, Rethorst CD, Ring KM, dela Cruz AM, Trivedi MH. Comorbidities and race/ethnicity among adults with stimulant use disorders in residential treatment. Journal of Ethnicity in Substance Abuse 2015;14(1):79-95.
-
Delivery of behavioral HIV prevention services in New York City outpatient substance abuse treatment clinics: Providers’ perspectives on opportunities and challenges.
Spector AY, Remien RH. Delivery of behavioral HIV prevention services in New York City outpatient substance abuse treatment clinics: Providers' perspectives on opportunities and challenges. AIDS Education and Prevention 2015;27(1):1-14.
-
A ‘Missing Not at Random’ (MNAR) and ‘Missing at Random’ (MAR) growth model comparison with a buprenorphine/naloxone clinical trial.
McPherson S, Barbosa-Leiker C, Mamey MR, McDonell M, Enders CK, Roll JM. A 'Missing Not at Random' (MNAR) and 'Missing at Random' (MAR) growth model comparison with a buprenorphine/naloxone clinical trial. Addiction 2015;110(1):51-58.
-
Denial of urinalysis-confirmed opioid use in prescription opioid dependence.
Hilario EY, Griffin ML, McHugh RK, McDermott KA, Connery HS, Fitzmaurice GM, Weiss RD. Denial of urinalysis-confirmed opioid use in prescription opioid dependence. Journal of Substance Abuse Treatment 2015;48(1):85-90.
-
Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper: A discrete survival and growth mixture model.
Northrup TF, Stotts AL, Green C, Potter JS, Marino EN, Walker NR, Weiss RD, Trivedi MH. Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper: A discrete survival and growth mixture model. Addictive Behaviors 2015;41:20-28.
-
Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs.
Schackman BR, Leff JA, Barter DM, DiLorenzo MA, Feaster DJ, Metsch LR, Freedberg KA, Linas BP. Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs. Addiction 2015;110(1):129-143.
-
Acceptability of a web-based community reinforcement approach for substance use disorders with treatment-seeking American Indians/Alaska Natives.
Campbell ANC, Turrigiano E, Moore M, Miele GM, Rieckmann TR, Hu M, Kropp FB, Ringor-Carty R, Nunes EV. Acceptability of a web-based community reinforcement approach for substance use disorders with treatment-seeking American Indians/Alaska Natives. Community Mental Health Journal 2015;51(4):393-403.
-
The multi-site Prescription Opioid Addiction Treatment Study: 18-month outcomes.
Potter JS, Dreifuss JA, Marino EN, Provost SE, Dodd DR, Rice LS, Fitzmaurice GM, Griffin ML, Weiss RD. The multi-site Prescription Opioid Addiction Treatment Study: 18-month outcomes. Journal of Substance Abuse Treatment 2015;48(1):62-69.